Tiny study probes bone microenvironment in metastatic kidney cancer

NCT ID NCT07187869

Recruiting now Knowledge-focused Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This early study will look at how two drugs, cabozantinib and nivolumab, change the bone immune environment in 16 people with kidney cancer that has spread to bone. The main goal is to check safety and see how the bone environment responds. It is a proof-of-concept study, meaning it is too small and early to know if this approach will work.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cabozantinib and nivolumab
What this could lead to: If successful, this could help identify better treatment options for kidney cancer that has spread to bone, potentially reducing bone complications.
What could go wrong: This is a very early, small proof-of-concept study with only 16 participants. The main goal is safety, not effectiveness, so results may not lead to new treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma nonpapillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLEAR CELL RENAL CELL CARCINOMA

Contacts and locations

Locations

The University of Texas M. D. Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.